title: New targets for antibody therapy of pediatric B cell lymphomas.
abstract: Antibody therapy has become standard of care for adult B cell lymphoma patients. It is a potentially less toxic and more targeted approach for lymphoma therapy and should therefore be applied to treat pediatric B cell lymphoma patients as well. In pediatric lymphoma patients, however, clinical experience with monoclonal antibodies is very limited. This is in part due to smaller patient numbers and very good outcome with conventional chemotherapy. In addition, pediatric patient and lymphoma biology differ significantly from that found in adults often precluding extrapolation of the adult experience to children. This review focuses on targeting pediatric B cell lymphoma with monoclonal antibody therapy. The special characteristics of B cell lymphomas found in children are reviewed and six potential new lymphoma target antigens are discussed.
authors.affiliation: Department of Pediatric Hematology and Oncology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, the Netherlands.
authors.forename: Annelies
authors.initials: A
authors.lastname: van Vuren
authors.forename: Friederike
authors.initials: F
authors.lastname: Meyer-Wentrup
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002648:Child; D006801:Humans; D007167:Immunotherapy; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000276:immunology*; D010372:Pediatrics; D011379:Prognosis
chemical_list: D000911:Antibodies, Monoclonal
keywords: Burkitt lymphoma; Hodgkin lymphoma; cancer immunotherapy; diffuse large B cell lymphoma; monoclonal antibodies; pediatric cancer